Zolbetuximab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - Claudiximab - GC 182 - IMAB 362 - IMAB-362 - IMAB362 - Vyloy - ZOLBETUXIMAB - Zolbetuximab-clzb